KOSPIHolding Companies002620

Jeil Pharma Holdings

₩7,480▲ 1.77%2026-10-02 close

Market Cap

₩119B

Turnover

₩26,122,060

Volume

3,540 shares

Shares out.

16M

PER

26.2×

PBR

0.4×

EPS

₩294

Dividend Yield

0.91%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩70 per share · Prices as of the 2026-10-02 close

Report overview

Holding Co. Back to Profit, Quarterly Swings Persist

Jeil Pharma Holdings returned to annual operating and net profit in 2025, but quarterly earnings swung sharply again in 2026, leaving the pipeline progress of its pharmaceutical subsidiary and grandchild company as the key variable for future results.

1
2025 consolidated operating profit of KRW 38.69bn and net profit of KRW 34.79bn marked a swing from prior-year losses
2
Q2 2026 posted an operating loss of about KRW 9.94bn and an owner-attributable net loss of about KRW 3.55bn, showing widened quarterly volatility
3
Core subsidiary Jeil Pharmaceutical is reducing reliance on distributed products and raising the share of its own new drug Jaqubo
4
Clinical progress of grandchild subsidiary Onconic Therapeutics' oncology candidate Nesuparib and diabetes candidate JP-2266 is a key variable for group valuation
5
Third-generation heir CEO Han Sang-cheol has continued purchasing holding company shares, signaling a gradual management succession process

Business structure

Jeil Pharma Holdings is a pure holding company overseeing subsidiaries including Jeil Pharmaceutical and Jeil Health Science, with group earnings heavily dependent on the business structure of core subsidiary Jeil Pharmaceutical.

Jeil Pharmaceutical has historically operated as a distribution-heavy business relying on products sourced from multinational drugmakers, with distributed-product sales accounting for 68.9% of revenue in 2024, far exceeding the 29.4% share of self-developed products.

Starting in 2025, the company discontinued distribution of three Viatris pain and anti-inflammatory products, Lyrica, Neurontin and Celebrex, making a reduction in distributed-product sales unavoidable.

In contrast, its self-developed acid-suppressing new drug Jaqubo was approved as Korea's 37th domestically developed new drug in April 2024 and launched in October that year, generating KRW 25.6bn in sales in the first half of 2025, or 8.5% of total revenue.

As a result, Jeil Pharmaceutical's own-product revenue share rose sharply from 29.4% in 2024 to 41.1% in the first half of 2025, while the distributed-goods share fell from 68.9% to 57.9% over the same period.

Jaqubo expanded its distribution network through a co-marketing agreement with Dong-A ST beginning September 2025, running for three years through October 2027 with a targeted sales amount of KRW 189.7bn.

New drug development is handled by research subsidiary Onconic Therapeutics, which Jeil Pharmaceutical established as a wholly owned entity in 2020 and which listed on KOSDAQ in December 2024; Jeil Pharmaceutical currently holds roughly a 45% stake, making Onconic a grandchild company under the holding structure.

Onconic combines licensing revenue from Jaqubo with clinical development of oncology candidate Nesuparib, serving as the external showcase for the group's new drug development capabilities.

Earnings trend

Quarterly revenue · Operating profit

₩159.8B₩6.9B25Q2₩161.4B₩18.1B25Q3₩154.4B₩6.6B25Q4₩150.4B₩3.6B26Q1₩164.7B-₩9.9B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩793B-₩7.5B2022₩804B₩20.8B2023₩779.8B-₩11.6B2024₩657.6B₩38.7B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩159.8B	₩6.9B	4.3%
2025Q3	₩161.4B	₩18.1B	11.2%
2025Q4	₩154.4B	₩6.6B	4.2%
2026Q1	₩150.4B	₩3.6B	2.4%
2026Q2	₩164.7B	-₩9.9B	−6.0%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩793B	-₩7.5B	-₩83.1B	−1.0%	−24.6%	106.2%
2023	₩804B	₩20.8B	-₩13.2B	2.6%	−4.1%	118.8%
2024	₩779.8B	-₩11.6B	-₩66.4B	−1.5%	−21.6%	103.6%
2025	₩657.6B	₩38.7B	₩14.6B	5.9%	4.6%	86.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Consolidated revenue in 2025 fell 15.8% year on year to KRW 657.6bn from KRW 779.8bn, while operating profit swung to KRW 38.69bn from an operating loss of KRW 11.56bn in 2024.

The company attributed the improvement to the absence of impairment losses on subsidiaries in 2025, in contrast to a one-off impairment charge recorded the prior year.

Net profit also improved sharply to KRW 34.79bn from a net loss of KRW 66.39bn, but profit attributable to owners of the parent was only KRW 14.64bn, less than half of total net profit, indicating a substantial income contribution accruing to non-controlling interests such as Onconic Therapeutics.

Looking at the trailing four quarters from Q3 2025 through Q2 2026, operating profit spiked to KRW 18.09bn in Q3 2025 before narrowing to KRW 6.55bn in Q4 and KRW 3.56bn in Q1 2026, then reversing into an operating loss of KRW 9.94bn with an owner-attributable net loss of KRW 3.55bn in Q2 2026 on revenue of KRW 164.70bn.

In 2023, the company posted an operating profit of KRW 20.82bn yet still recorded a net loss of KRW 13.24bn, illustrating a recurring pattern where non-operating items such as impairments and financial gains or losses have repeatedly determined the annual bottom line beyond the operating result.

Operating cash flow was only KRW 0.39bn in 2025, down from KRW 4.54bn in 2024, suggesting that the return to accounting profit was not fully matched by an improvement in cash generation.

The debt ratio eased from 118.8% in 2023 and 103.6% in 2024 to 86.9% in 2025, pointing to a somewhat improved balance sheet structure.

Industry analysis

Korea's pharmaceutical industry is in the midst of a structural shift from traditional distribution of multinational products toward self-developed new drugs and improved formulations, and Jeil Pharmaceutical Group's recent moves track this broader industry trend.

Distribution-focused drugmakers face persistent exposure to government drug-price cuts and the risk of losing distribution rights when multinational partners renegotiate contracts, driving intense industry-wide competition to diversify portfolios with proprietary or improved new drugs.

In the P-CAB (potassium-competitive acid blocker) gastrointestinal treatment segment, incumbent products such as HK inno.N's Ketcap already hold market share, positioning Jaqubo as a later entrant pursuing both prescription growth and overseas technology licensing.

In oncology, numerous domestic biotechs and pharmaceutical companies are pursuing global partnerships through dual-target mechanisms and orphan drug designations, and Onconic Therapeutics' Nesuparib is likewise leveraging a U.S.

FDA orphan drug designation to enhance its clinical asset value within this competitive landscape.

In the diabetes treatment market, attention has concentrated on the global commercial success of GLP-1 class drugs, positioning the SGLT-mechanism candidate JP-2266 as a differentiated oral therapy attempting to carve out a distinct niche domestically and internationally.

Because Onconic Therapeutics is separately listed under the holding structure, the market has already partially priced in the value of its drug pipeline, meaning the holding company's shares represent indirect exposure to that pipeline value.

Outlook

Jeil Pharmaceutical's self-developed oral type 2 diabetes candidate JP-2266 had its Phase 2 clinical results published in the international journal Diabetes and Metabolism Journal in July 2026, externally confirming improvements in postprandial glucose and HbA1c.

In that trial, the proportion of patients achieving HbA1c below 7.0% was 70.6% in the 10mg JP-2266 group and 66.7% in the 5mg group, with statistically significant estimated treatment differences versus placebo in both dose groups.

JP-2266 is designed as a dual inhibitor targeting renal SGLT-2 and intestinal SGLT-1 simultaneously, and whether and when it advances into Phase 3 trials is the key variable for the next stage.

Grandchild subsidiary Onconic Therapeutics' dual-target oncology candidate Nesuparib received Korean regulatory approval for a Phase 2 IND targeting locally advanced or metastatic pancreatic cancer in September 2025, and has also reportedly received U.S. FDA orphan drug designation for small cell lung cancer.

Jaqubo is in the process of expanding its prescription base through co-marketing with Dong-A ST, and whether it achieves the targeted sales amount of KRW 189.7bn set for the contract period through October 2027 is a key point to watch for Jeil Pharmaceutical's product revenue growth.

Third-generation heir Han Sang-cheol, who serves as co-CEO of Jeil Pharmaceutical and an unregistered executive at Onconic Therapeutics, is strengthening ties across group affiliates, raising the possibility that future management succession and new drug development milestones will unfold in tandem.

Valuation

PER

26.2×

PBR

0.4×

ROE

1.5%

EPS

₩294

BPS

₩20,462

Dividend per share

₩70

The price-to-book ratio trades at a discount to net asset value, indicating the market values the shares below their per-share book value.

However, the price-to-earnings ratio calculated from the 2025 annual return to profit and the trailing four-quarter profit level appears notably elevated, a result that warrants caution given how small and volatile the underlying earnings base has been amid sharp quarterly swings.

On the dividend side, the dividend yield derived from the disclosed per-share cash dividend divided by the current price runs below the industry average, suggesting the stock tends to be approached less for dividend appeal and more for holding company asset value and the pipeline progress of its subsidiary and grandchild company.

On the equity side, capital attributable to owners of the parent has fluctuated since 2022 and has not yet fully recovered to earlier levels, while non-controlling interests still represent a meaningful share of total equity, a structural factor worth considering when interpreting the holding company's equity value.

Taken together, this is a segment where a discount on a book-value basis coexists with an elevated multiple on a recent-earnings basis, two signals that can point to different conclusions depending on which metric is weighted more heavily.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Annual Return to Profit and Improved Balance Sheet

Consolidated operating profit and net profit both swung to positive in 2025 versus the prior year, and the debt ratio improved from 118.8% in 2023 to 86.9% in 2025, indicating a strengthened balance sheet.

This largely reflects the disappearance of the one-off impairment burden recorded the prior year, but the resulting improvement in the reported profit and loss trend is clear. This could be a positive factor for the group's overall creditworthiness and financing conditions.

Shift Toward Own-Product Revenue Led by Jaqubo

Jeil Pharmaceutical is shifting its business mix from a distribution-dependent model toward greater reliance on revenue from its self-developed drug Jaqubo.

Own-product revenue share rose sharply to 41.1% in the first half of 2025 from 29.4% the prior year, and Jaqubo is expanding its distribution network through co-marketing with Dong-A ST.

If this structural shift continues, earnings sensitivity to external factors such as the loss of distributed-product licenses could diminish.

Pipeline Clinical Progress and Owner Share Purchases

Diabetes candidate JP-2266 had its Phase 2 results published in an international journal, and oncology candidate Nesuparib received U.S. FDA orphan drug designation, showing that new drug development at the subsidiary and grandchild company is progressing in stages.

At the same time, CEO Han Sang-cheol purchased 70,000 and 80,000 common shares of the holding company on the open market in June and July 2026 respectively, raising his stake from 9.70% to 10.14%. This reflects an ongoing pattern of management share accumulation, though its interpretation is left to investors.

Bear factors

Widening Quarterly Volatility and Recent Return to Loss

Operating profit fell from KRW 18.09bn in Q3 2025 to KRW 6.55bn in Q4 and KRW 3.56bn in Q1 2026, before reversing into an operating loss of KRW 9.94bn and an owner-attributable net loss of KRW 3.55bn in Q2 2026. This confirms that even though the annual result turned positive, the quarterly trend remains unstable. Such volatility adds to the difficulty of forecasting future performance.

Questions Over Earnings Quality and Cash Generation

Operating cash flow in 2025 was only KRW 0.39bn, down from KRW 4.54bn in 2024, meaning the return to accounting profit was not fully matched by improved cash generation.

In addition, profit attributable to owners of the parent came in at less than half of total net profit, confirming that a substantial portion of earnings is allocated to non-controlling interests.

This means the profit actually accruing to holding company shareholders can be smaller than the headline total net profit figure suggests.

Revenue Contraction from Loss of Distributed-Product Rights

Starting in 2025, the discontinuation of distribution for three Viatris pain and anti-inflammatory products, Lyrica, Neurontin and Celebrex, reduced distributed-product sales, a key factor behind the 15.8% year-on-year decline in 2025 annual revenue.

While self-developed product revenue is growing, it has not yet fully offset the decline in distributed-product sales. The possibility of similar licensing renegotiation risks recurring in the future cannot be ruled out.

Risk factors

Clinical Development Risk

Both JP-2266 and Nesuparib remain in Phase 3 or late Phase 2 clinical stages, meaning additional clinical success and time are needed before final approval or licensing deals can be finalized.

Clinical trials tend to carry greater failure risk and cost burden as they progress to later stages, so the possibility of delays or discontinuation cannot be ruled out. This is a factor with direct implications for the valuation of the group's new drug pipeline.

Earnings Structure and Non-Controlling Interest Risk

Because Onconic Therapeutics is separately listed and Jeil Pharmaceutical's stake is only around 45%, a substantial share of the subsidiary's profit growth may continue to accrue to non-controlling interests.

This means that even as consolidated total net profit rises, the increase in profit actually felt by holding company shareholders could be limited. Future changes in ownership stakes or additional share purchases are also variables to watch.

Uncertainty Related to Management Succession

While second-generation Chairman Han Seung-soo remains the largest shareholder with a 57.80% stake in the holding company, the transfer of management control to his eldest son, CEO Han Sang-cheol, has not yet been completed in terms of share transfer.

With inheritance or gift tax burdens estimated to reach the tens of billions of won, the method and timing of succession could bring changes to governance or ownership structure. This succession issue is a factor that could directly or indirectly affect shareholder value and warrants ongoing monitoring.

What to watch next

Mid-November 2026
Q3 2026 earnings disclosure (preliminary) should be checked to see whether the company exits the Q2 loss and how much equity-method income from Onconic Therapeutics is reflected.
From the second half of 2026 onward
Watch for disclosures on whether and when an investigational new drug (IND) application for a Phase 3 trial of diabetes candidate JP-2266 is submitted.
From the second half of 2026 onward
Additional Phase 2 clinical data readouts and any technology licensing discussion disclosures for Onconic Therapeutics' oncology candidate Nesuparib (ovarian, pancreatic, small cell lung cancer) should be monitored.
From the second half of 2026 onward
Check for disclosures on additional share purchases or gift transactions involving CEO Han Sang-cheol and related parties to track the progress of management succession.
Through the contract's expiration in October 2027
Progress toward the KRW 189.7bn target sales amount under Jaqubo's co-marketing agreement with Dong-A ST should be continuously tracked through quarterly revenue figures.

Overall view

Jeil Pharma Holdings returned to operating and net profit on an annual basis in 2025, aided by the disappearance of impairment charges, and its balance sheet improved with a lower debt ratio, but quarterly earnings in 2026 gradually weakened after peaking in Q3 2025 and reverted to an operating and net loss in Q2, revealing continued volatility.

Core subsidiary Jeil Pharmaceutical is undergoing a structural shift to reduce reliance on distributed products and raise the revenue share of its own new drug Jaqubo, while pursuing distribution expansion through a co-marketing partnership with Dong-A ST.

Nesuparib, the oncology candidate developed by grandchild subsidiary Onconic Therapeutics, and JP-2266, Jeil Pharmaceutical's diabetes drug candidate, have each achieved milestones such as U.S.

FDA orphan drug designation and publication of Phase 2 clinical results in an international journal, but further clinical work and time are needed before final commercialization.

A structure in which profit attributable to owners of the parent falls short of half of total net profit, combined with operating cash flow that declined even as accounting profit improved, are factors worth weighing when assessing earnings quality.

Amid continued share purchases by third-generation heir CEO Han Sang-cheol, management succession and the commercialization progress of the new drug pipeline remain the key variables that will shape the group's future direction.

Investors should continue to monitor quarterly earnings volatility, clinical development timelines, and succession-related share changes before forming any investment judgment.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.